SAB Biotherapeutics is a clinical-stage biotech centered on SAB-142, a disease-modifying T1D candidate targeting both stage 2 and stage 3 patients. SAB-142 may preserve beta-cell function and ...
Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results